These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 15883488)

  • 1. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone].
    Richard C; Bibas P; Lablache-Combier M; Allaire C
    J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Value of the conjunctival provocation test in evaluating the activity of 2 concentrations of anti-allergy eyedrops, mequitazine].
    Dupin O; Compeyre S; Trinquand C; Persi L; Arnaud B
    J Fr Ophtalmol; 1998 Jan; 21(1):12-8. PubMed ID: 9834894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus.
    Mortemousque B; Jacquet A; Richard C; Depont F; Colin J; Moore N
    Br J Ophthalmol; 2004 Mar; 88(3):336-40. PubMed ID: 14977764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of topical mequitazine and disodium cromoglycate in allergic conjunctivitis induced by a specific conjunctival provocation test.
    Dupin O; Trinquand C; Persi L; Bousquet J; Robert F; Arnaud B
    Eur J Ophthalmol; 2000; 10(1):15-21. PubMed ID: 10744200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Safety and efficacy of a new preservative-free levocabastine ophthalmic solution (Levofree®) using the conjunctival provocation test].
    Allaire C; Siou-Mermet R; Bassols A
    J Fr Ophtalmol; 2012 Sep; 35(7):491-8. PubMed ID: 22498504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model.
    Friedlaender MH; Harris J; LaVallee N; Russell H; Shilstone J
    Ophthalmology; 2000 Dec; 107(12):2152-7. PubMed ID: 11097587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy of olopatadine 0.1% ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challenge model.
    Abelson MB; Greiner JV
    Curr Med Res Opin; 2004 Dec; 20(12):1953-8. PubMed ID: 15701212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of mequitazine in comparison with placebo assessed by ocular challenge with allergen in allergic conjunctivitis.
    Persi L; Dupin O; Arnaud B; Trinquand C; Michel FB; Bousquet J
    Allergy; 1997 Apr; 52(4):451-4. PubMed ID: 9188930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model.
    Netland PA; Leahy C; Krenzer KL
    Am J Ophthalmol; 2000 Dec; 130(6):717-23. PubMed ID: 11124289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of effects of topical levocabastine and nedocromil sodium on the early response in a conjunctival provocation test with allergen.
    Hammann C; Kämmerer R; Gerber M; Spertini F
    J Allergy Clin Immunol; 1996 Dec; 98(6 Pt 1):1045-50. PubMed ID: 8977503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of levocabastine in conjunctival provocation studies.
    Janssens M
    Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis.
    Abelson MB; George MA; Schaefer K; Smith LM
    J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model.
    Lanier BQ; Finegold I; D'Arienzo P; Granet D; Epstein AB; Ledgerwood GL
    Curr Med Res Opin; 2004 Aug; 20(8):1227-33. PubMed ID: 15324525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of levocabastine, a new H1 antagonist, in a conjunctival provocation test with allergens.
    Zuber P; Pécoud A
    J Allergy Clin Immunol; 1988 Oct; 82(4):590-4. PubMed ID: 2902114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of levocabastine hydrochloride ophthalmic suspension in the conjunctival allergen challenge test in Japanese subjects with seasonal allergic conjunctivitis.
    Takamura E; Nomura K; Fujishima H; Fukagawa K; Satake Y; Fukada Y; Sawa M; Uchida E
    Allergol Int; 2006 Jun; 55(2):157-65. PubMed ID: 17075252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis.
    Verin P; Easty DL; Secchi A; Ciprandi G; Partouche P; Nemeth-Wasmer G; Brancato R; Harrisberg CJ; Estivin-Ebrardt C; Coster DJ; Apel AJ; Coroneo MT; Knorr M; Carmichael TR; Kent-Smith BT; Abrantes P; Leonardi A; Cerqueti PM; Modorati G; Martinez M
    Am J Ophthalmol; 2001 Jun; 131(6):691-8. PubMed ID: 11384563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of topical 0.05% levocabastine and 0.1% lodoxamide in patients with allergic conjunctivitis. Study Group.
    Richard C; Trinquand C; Bloch-Michel E
    Eur J Ophthalmol; 1998; 8(4):207-16. PubMed ID: 9891891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.